Estonija - estonščina - Ravimiamet

sandoz pharmaceuticals d.d. - drospirenoon+etünüülöstradiool - õhukese polümeerikattega tablett - 0+0/3mg+0,03mg 42tk / 126tk; 0+0/3mg+0,03mg 91tk / 273tk; 0+0/3mg+0,03mg 21tk / 63tk; 0+0/3mg+0,03mg 7tk / 21tk; 0+0/3mg+0,03mg 14tk / 42tk

Estonija - estonščina - Ravimiamet

sandoz pharmaceuticals d.d. - drospirenoon+etünüülöstradiool - õhukese polümeerikattega tablett - 0+0/3mg+0,02mg 91tk / 273tk; 0+0/3mg+0,02mg 21tk / 63tk; 0+0/3mg+0,02mg 14tk / 42tk; 0+0/3mg+0,02mg 42tk / 126tk

Estonija - estonščina - Ravimiamet

pharmaswiss ceska republika s.r.o. - drospirenoon+etünüülöstradiool - õhukese polümeerikattega tablett - 0+0/3mg+0,02mg 21tk / 63tk; 0+0/3mg+0,02mg 14tk / 42tk; 0+0/3mg+0,02mg 7tk / 21tk; 0+0/3mg+0,02mg 91tk / 273tk

Evropska unija - estonščina - EMA (European Medicines Agency)

pfizer europe ma eeig - moroktokog alfa - hemofiilia a. - antihemorraagilised ained - verejooksu ravi ja profülaktika hemofiilia a patsientidel (kaasasündinud faktor viii puudulikkus). refacto af sobib kasutamiseks täiskasvanutele ja lastele igas vanuses, sealhulgas vastsündinud. refacto af ei sisalda von-willebrand faktorit ja ei ole seega näidustatud von-willebrand ' s disease.

Evropska unija - estonščina - EMA (European Medicines Agency)

csl behring gmbh - lonoktokog alfa - hemofiilia a. - antihemorraagilised ained - verejooksu ravi ja profülaktika hemofiilia a patsientidel (kaasasündinud viii faktori puudulikkus). afstyla võib kasutada kõikides vanuserühmades.

Evropska unija - estonščina - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Estonija - estonščina - Ravimiamet

teva pharma b.v. - olmesartaanmedoksomiil - õhukese polümeerikattega tablett - 10mg 28tk; 10mg 98tk; 10mg 90tk; 10mg 14tk; 10mg 56tk; 10mg 30tk

Estonija - estonščina - Ravimiamet

teva pharma b.v. - olmesartaanmedoksomiil - õhukese polümeerikattega tablett - 20mg 28tk; 20mg 90tk; 20mg 30tk; 20mg 14tk; 20mg 56tk

Estonija - estonščina - Ravimiamet

teva pharma b.v. - olmesartaanmedoksomiil - õhukese polümeerikattega tablett - 40mg 28tk; 40mg 98tk; 40mg 30tk; 40mg 14tk; 40mg 90tk; 40mg 56tk

Estonija - estonščina - Ravimiamet

tillotts pharma ab - mesalasiin - toimeainet modifitseeritult vabastav tablett - 800mg 50tk; 800mg 10tk